Registration for a live webinar on 'Innovative Vaccines and Viral Pathogenesis: Insights from Recent Monkeypox Research' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Overview
- Adipose tissue effect on various tissues
- Adipose tissue involved in different processes
- The two steps of weight gain
- Hypertrophic adipocytes
- Hypertrophic adipocytes attract macrophages
- Macrophages clear the necrotic adipocytes
- Dysfunctional adipose tissue and inflammation
- Collagens in adipose tissue
- Adipocytes factors involved in inflammation
- The adipokine panel for clinical studies
- Why is the adipokine panel a useful marker
- Impact of visceral fat pad on the liver
- Impact of adipokines (IL-6) on the liver
- RBP4 levels are proportional to BMI and insulin
- RBP4 and glucose disposal
- Resistin
- Serum resistin levels in patients with CAD
- Adiponectin
- Adiponectin in various physiological conditions
- Adiponectin multimerization
- Adiponectin distribution in man and women
- Adiponectin distribution in obesity
- What makes adiponectin a good biomarker
- Adiponectin as a prospective marker of CVD
- Adiponectin and MI
- HMW adiponectin and CAD
- Adiponectin as a mortality predictor
- Hepatic insulin sensitizer
- Adiponectin and insulin sensitivity
- Adiponectin levels in type 2 diabetes
- HMW adiponectin and insulin resistance
- Anti-steatotic action of adiponectin
- Adiponectin and liver histology
- A mediator of PPAR-gamma agonist action
- Insulin sensitivity and HMW adiponectin
- Adiponectin increase and hepatic insulin sensitivity
- PPAR-gamma agonist: less effective in ADN KO
- Adiponectin and hypertension
- Adiponectin as a risk factor for hypertension
- Adiponectin in renal failure
- Adiponectin in cancer
- Overexpression of adiponectin in ob/ob mice
- Overexpression of adiponectin - results (1)
- Overexpression of adiponectin - results (2)
- Overexpression of adiponectin - results (3)
- Subcutaneous fat as a "metabolic sink"
- Summary
- Acknowledgements
Topics Covered
- Adipose tissue as an endocrine organ
- Local and systemic inflammation increases due to dysfunctional adipose tissue
- Dysfunctional adipose tissue is more fibrotic
- Factors involved in inflammation
- Factors involved in energy homeostasis
- The Adipokine panel for clinical studies
- Impact of visceral fat pad on liver
- Retinol binding protein 4 (RBP4)
- Resistin
- Adiponectin
- Adiponectin multimerization
- Prospective marker of CVD
- Hepatic insulin sensitizer
- Anti-steatotic action of Adiponectin
- A mediator of PPARg agonist action
- Type 2 diabetic patients
- Hypertension
- Renal failure
- Cancer
- Transgenic overexpression of Adiponectin in ob/ob mice
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Scherer, P. (2015, November 24). Obesity and adiponectin [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 11, 2024, from https://doi.org/10.69645/ADVD2505.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Philipp Scherer has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Clinical Practice
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, my name is Philipp Scherer.
I market Touchstone Diabetes Center at the University of Texas,
Southwestern Medical Center, in Dallas Texas.
It is my pleasure to talk to you today about
the endocrine functions of adipose tissue with
a particularly emphasis on the adipocyte-specific secretory protein, adiponectin.
0:23
I will structure my talk into four different sections.
I will start out by discussing adipose tissue as an endocrine organ.
We'll go through some hallmarks of dysfunctional adipose tissue and
then follow up with our general discussion
of fat-derived factors that we generally refer to as adipokines.
Finally, I'll spend a significant amount of time
discussing the physiological role and the use of adiponectin as a clinical marker.
1:01
Adipose tissue is ubiquitously distributed and system wide,
there's not a single cell that's not affected
directly or indirectly by fat-derived factors.
These factors include lipid factors as well as protein-based hormonal factors,
and key tissues that have been studied over the years include the vasculature, liver,
the heart, pancreatic beta cells,
as well as the reproductive tract,
the brain, and muscle.
1:34
Predictably, fat-derived factors have a profound impact on energy metabolism.
However, the last couple of years have also shown that
adipocyte-derived factors have a profound impact on systemic and local inflammation,
and vice versa, systemic inflammation has
a profound impact on the pattern of adipocyte-derive secretory factors.
In addition, fat-derived factors also play
a role in the context of cancer, supporting tumor growth,
for instance, in the context of breast cancer,
and they also play a role in the context -of infectious disease models.